Diagnostic and prognostic biomarkers reflective of cardiac remodelling in diabetes mellitus: A scoping review.

Chhor, M; Law, W; Pavlovic, M; Aksentijevic, D; McGrath, K; McClements, L

Diagnostic and prognostic biomarkers reflective of cardiac remodelling in diabetes mellitus: A scoping review.

Chhor, M Law, W Pavlovic, M Aksentijevic, D McGrath, K

McClements, L

Permalink

Publisher:: WILEY
Publication Type:: Journal Article
Citation:: Diabet Med, 2023, 40, (5), pp. e15064
Issue Date:: 2023-05

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Published versionAdobe PDF (339.68 kB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Chhor, M
dc.contributor.author	Law, W
dc.contributor.author	Pavlovic, M
dc.contributor.author	Aksentijevic, D
dc.contributor.author	McGrath, K https://orcid.org/0000-0002-6244-3929
dc.contributor.author	McClements, L https://orcid.org/0000-0002-4911-1014
dc.date.accessioned	2024-02-12T06:02:27Z
dc.date.available	2023-02-07
dc.date.available	2024-02-12T06:02:27Z
dc.date.issued	2023-05
dc.identifier.citation	Diabet Med, 2023, 40, (5), pp. e15064
dc.identifier.issn	0742-3071
dc.identifier.issn	1464-5491
dc.identifier.uri	http://hdl.handle.net/10453/175584
dc.description.abstract	AIMS: The aim of this scoping review is to evaluate the current biomarkers used in the assessment of adverse cardiac remodelling in people with diabetes mellitus (DM) and in the diagnosis and prognosis of subsequent cardiovascular disease. We aim to discuss the biomarkers' pathophysiological roles as a reflection of the cardiac remodelling mechanisms in the presence of DM. METHODS: We performed the literature search to include studies from 2003 to 2021 using the following databases: MEDLINE, Scopus, Web of Science, PubMed, and Cochrane library. Articles that met our inclusion criteria were screened and appraised before being included in this review. The PRISMA guidelines for Scoping Reviews were followed. RESULTS: Our literature search identified a total of 43 eligible articles, which were included in this scoping review. We identified 15 different biomarkers, each described by at least two studies, that were used to determine signs of cardiac remodelling in cardiovascular disease (CVD) and people with DM. NT-proBNP was identified as the most frequently employed biomarker in this context; however, we also identified emerging biomarkers including hs-CRP, hs-cTnT, and Galectin-3. CONCLUSION: There is a complex relationship between DM and cardiovascular health, where more research is needed. Current biomarkers reflective of adverse cardiac remodelling in DM are often used to diagnose other CVDs, such as NT-proBNP for heart failure. Hence there is a need for identification of specific biomarkers that can detect early signs of cardiac remodelling in the presence of DM. Further research into these biomarkers and mechanisms can deepen our understanding of their role in DM-associated CVD and lead to better preventative therapies.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	WILEY
dc.relation.ispartof	Diabet Med
dc.relation.isbasedon	10.1111/dme.15064
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	1103 Clinical Sciences, 1117 Public Health and Health Services, 1701 Psychology
dc.subject.classification	Endocrinology & Metabolism
dc.subject.classification	3202 Clinical sciences
dc.subject.mesh	Humans
dc.subject.mesh	Prognosis
dc.subject.mesh	Cardiovascular Diseases
dc.subject.mesh	Ventricular Remodeling
dc.subject.mesh	Diabetes Mellitus
dc.subject.mesh	Biomarkers
dc.subject.mesh	Humans
dc.subject.mesh	Cardiovascular Diseases
dc.subject.mesh	Diabetes Mellitus
dc.subject.mesh	Prognosis
dc.subject.mesh	Ventricular Remodeling
dc.subject.mesh	Biomarkers
dc.subject.mesh	Humans
dc.subject.mesh	Prognosis
dc.subject.mesh	Cardiovascular Diseases
dc.subject.mesh	Ventricular Remodeling
dc.subject.mesh	Diabetes Mellitus
dc.subject.mesh	Biomarkers
dc.title	Diagnostic and prognostic biomarkers reflective of cardiac remodelling in diabetes mellitus: A scoping review.
dc.type	Journal Article
utslib.citation.volume	40
utslib.location.activity	England
utslib.for	1103 Clinical Sciences
utslib.for	1117 Public Health and Health Services
utslib.for	1701 Psychology
pubs.organisational-group	University of Technology Sydney
pubs.organisational-group	University of Technology Sydney/Faculty of Science
pubs.organisational-group	University of Technology Sydney/Strength - CHT - Health Technologies
pubs.organisational-group	University of Technology Sydney/Faculty of Science/School of Life Sciences
pubs.organisational-group	University of Technology Sydney/Centre for Health Technologies (CHT)
utslib.copyright.status	open_access	*
dc.date.updated	2024-02-12T06:02:26Z
pubs.issue	5
pubs.publication-status	Published
pubs.volume	40
utslib.citation.issue	5

Abstract:

AIMS: The aim of this scoping review is to evaluate the current biomarkers used in the assessment of adverse cardiac remodelling in people with diabetes mellitus (DM) and in the diagnosis and prognosis of subsequent cardiovascular disease. We aim to discuss the biomarkers' pathophysiological roles as a reflection of the cardiac remodelling mechanisms in the presence of DM. METHODS: We performed the literature search to include studies from 2003 to 2021 using the following databases: MEDLINE, Scopus, Web of Science, PubMed, and Cochrane library. Articles that met our inclusion criteria were screened and appraised before being included in this review. The PRISMA guidelines for Scoping Reviews were followed. RESULTS: Our literature search identified a total of 43 eligible articles, which were included in this scoping review. We identified 15 different biomarkers, each described by at least two studies, that were used to determine signs of cardiac remodelling in cardiovascular disease (CVD) and people with DM. NT-proBNP was identified as the most frequently employed biomarker in this context; however, we also identified emerging biomarkers including hs-CRP, hs-cTnT, and Galectin-3. CONCLUSION: There is a complex relationship between DM and cardiovascular health, where more research is needed. Current biomarkers reflective of adverse cardiac remodelling in DM are often used to diagnose other CVDs, such as NT-proBNP for heart failure. Hence there is a need for identification of specific biomarkers that can detect early signs of cardiac remodelling in the presence of DM. Further research into these biomarkers and mechanisms can deepen our understanding of their role in DM-associated CVD and lead to better preventative therapies.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/175584